NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4 percent as compared to the fourth quarter of 2014. Operational sales results increased 4.4 percent and the negative impact of currency was 6.8 percent.

Domestic sales increased 8.0 percent. International sales decreased 11.7 percent, reflecting operational growth of 1.2 percent and a negative currency impact of 12.9 percent. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8 percent, domestic sales increased 13.4 percent and international sales increased 2.9 percent.

Worldwide sales for the full-year 2015 were $70.1 billion, a decrease of 5.7 percent versus 2014. Operational results increased 1.8 percent and the negative impact of currency was 7.5 percent. Domestic sales increased 2.6 percent. International sales decreased 13.1 percent, reflecting operational growth of 1.1 percent and a negative currency impact of 14.2 percent. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 6.5 percent, domestic sales increased 10.6 percent and international sales increased 3.0 percent.

Johnson & Johnson’s Vision Care unit, which is part of its Medical Devices division, reported $648 million in worldwide sales for the fourth quarter, a 0.3 percent increase over year ago. Operational sales for the unit rose 8.4 percent increase, and the negative impact of currency was 8.1 percent.

Domestic sales of Vision Care product climbed to $239 million in fourth quarter, up 22.6 percent from year ago; operation sales also rose 22.6 percent from year ago.

On a 12-month basis, worldwide sales of Vision Care products amounted to $2.6 billion, down 7.5 percent from 2014. Operational sales for 2015 rose 1.7 percent, with a negative currency effect of 9.2 percent. Domestic sales of Vision Care products totaled $997 million in 2015, up 2.3 percent from year ago; operational sales also rose 2.3 percent.

"Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our Pharmaceutical business and iconic Consumer brands,” said Alex Gorsky, chairman and chief executive officer. “As we enter 2016, our core business is very healthy, and the recent decisive actions we’ve taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we compete in.”

On Jan. 19, Johnson & Johnson announced a restructuring of certain Medical Devices businesses. However, the company’s Consumer Medical Devices businesses, Vision Care and Diabetes Care, are not impacted by the restructuring.